Three FDA Advisors Resign over Agency's Approval of Shoddy New Alzheimer's Drug

In November 2020, an independent panel slammed Aduhelm, a new Alzheimer's drug just approved by the FDA. When asked if there was supportive evidence for the use of this drug, zero out of the seven panel members said yes.

"The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients," reported the New York Times.

Full Episode: https://thehighwire.com

Support my work with a Substack subscription: http://vigilantfox.substack.com

Read my articles: http://redvoicemedia.com/vigilantfox

Follow my other socials: http://vigilantfox.id

Save big on MyPillow products at http://mypillow.com/vfox

“The best coffee you’ll ever try”: https://mystore.com/vfox

Save 5% off Z-Stack with coupon code FOX: https://zstacklife.com/?ref=wmpgvtrNa6bk

Protect your wealth from Bidenflation: https://www.gcjdjhs3e.com/3N116J/PS824/?uid=19